This indicator highlights the percentage of women who had a live birth within the last two years and received preventative anti-malarial treatment during their pregnancy, specifically focusing on the administration of two or more doses of SP/Fansidar. It serves as a critical measure of maternal health interventions aimed at reducing malaria-related morbidity and mortality among pregnant women, a vulnerable demographic. By tracking this data, health organizations can better understand the efficacy of malaria prevention strategies, identify gaps in service delivery, and enhance outreach programs to ensure that more pregnant women receive the necessary preventative care. Additionally, this indicator reflects broader public health efforts to improve maternal and child health outcomes in malaria-endemic regions.
Source: